Patient-Friendly Explanation
Retatrutide is a new weight loss medication currently being studied that works on three different hormone pathways at once — think of it as targeting weight loss from multiple angles simultaneously. In research trials, people taking Retatrutide lost an average of over 24% of their body weight, making it one of the most promising treatments in development.
Clinical Definition
Retatrutide (LY3437943) is a single peptide with triple-agonist activity at GLP-1, GIP, and glucagon receptors. Phase 2 clinical trial data (NEJM 2023) demonstrated mean weight reductions of up to 24.2% at 48 weeks with the highest dose, versus 2.1% with placebo. The glucagon receptor agonism is believed to increase energy expenditure, complementing the appetite-suppressive effects of GLP-1/GIP agonism.
Why It Matters
The field of medical weight management is advancing rapidly. At NuLifeCare, Dr. Joseph Wang stays current with emerging treatments like Retatrutide so you have access to the latest evidence-based options as they become available in Singapore.